OBJECTIVE: The aim of this study was to estimate associations of obesity with reproductive hormone levels as women progress from premenopausal to postmenopausal status. METHODS: This was a longitudinal study conducted in the population-based Penn Ovarian Aging Cohort (N = 436). At cohort enrollment, the women were premenopausal, ages 35 to 47 years, with equal numbers of African Americans and whites. Anthropometric measures, menopause status, and reproductive hormone measures were evaluated for 12 years. Associations of the anthropometric measures with estradiol, follicle-stimulating hormone, and inhibin B in the menopausal transition were estimated using generalized linear regression models for repeated measures. RESULTS: Associations between obesity and hormone levels differed by menopause status as indicated by significant interactions between each hormone and menopausal stage. Premenopausal obese and overweight women had significantly lower estradiol levels compared with nonobese women, independent of age, race, and smoking (obese: 32.8 pg/mL [95% CI, 30.6-35.2] vs nonobese: 39.8 pg/mL [95% CI, 37.0-42.8], P < 0.001). The associations reversed postmenopause, with obese women having the highest estradiol levels (obese: 20.6 pg/mL [95% CI, 17.2-24.7] vs nonobese: 12.2 pg/mL [95% CI, 10.1-14.8], P < 0.001). Inhibin B levels were significantly lower in premenopausal obese compared with nonobese women but reversed in the late transition stage. Follicle-stimulating hormone levels were lowest in postmenopausal obese compared with nonobese women (P < 0.001). Measures of waist circumference (central adiposity) and waist-to-hip ratio paralleled the body mass index results. CONCLUSION: Obesity is an important factor in hormone dynamics independent of age, race, and smoking in midlife women, although the mechanisms remain unclear.
OBJECTIVE: The aim of this study was to estimate associations of obesity with reproductive hormone levels as women progress from premenopausal to postmenopausal status. METHODS: This was a longitudinal study conducted in the population-based Penn Ovarian Aging Cohort (N = 436). At cohort enrollment, the women were premenopausal, ages 35 to 47 years, with equal numbers of African Americans and whites. Anthropometric measures, menopause status, and reproductive hormone measures were evaluated for 12 years. Associations of the anthropometric measures with estradiol, follicle-stimulating hormone, and inhibin B in the menopausal transition were estimated using generalized linear regression models for repeated measures. RESULTS: Associations between obesity and hormone levels differed by menopause status as indicated by significant interactions between each hormone and menopausal stage. Premenopausal obese and overweight women had significantly lower estradiol levels compared with nonobese women, independent of age, race, and smoking (obese: 32.8 pg/mL [95% CI, 30.6-35.2] vs nonobese: 39.8 pg/mL [95% CI, 37.0-42.8], P < 0.001). The associations reversed postmenopause, with obesewomen having the highest estradiol levels (obese: 20.6 pg/mL [95% CI, 17.2-24.7] vs nonobese: 12.2 pg/mL [95% CI, 10.1-14.8], P < 0.001). Inhibin B levels were significantly lower in premenopausal obese compared with nonobese women but reversed in the late transition stage. Follicle-stimulating hormone levels were lowest in postmenopausal obese compared with nonobese women (P < 0.001). Measures of waist circumference (central adiposity) and waist-to-hip ratio paralleled the body mass index results. CONCLUSION:Obesity is an important factor in hormone dynamics independent of age, race, and smoking in midlife women, although the mechanisms remain unclear.
Authors: H G Burger; E C Dudley; J L Hopper; N Groome; J R Guthrie; A Green; L Dennerstein Journal: J Clin Endocrinol Metab Date: 1999-11 Impact factor: 5.958
Authors: H Irene Su; Mary D Sammel; Ellen W Freeman; Hui Lin; Tracey DeBlasis; Clarisa R Gracia Journal: Menopause Date: 2008 Sep-Oct Impact factor: 2.953
Authors: Rebecca C Thurston; MaryFran R Sowers; Barbara Sternfeld; Ellen B Gold; Joyce Bromberger; Yuefang Chang; Hadine Joffe; Carolyn J Crandall; L Elaine Waetjen; Karen A Matthews Journal: Am J Epidemiol Date: 2009-08-12 Impact factor: 4.897
Authors: Siobán D Harlow; Margery Gass; Janet E Hall; Roger Lobo; Pauline Maki; Robert W Rebar; Sherry Sherman; Patrick M Sluss; Tobie J de Villiers Journal: J Clin Endocrinol Metab Date: 2012-02-16 Impact factor: 5.958
Authors: Rachel P Wildman; Ping G Tepper; Sybil Crawford; Joel S Finkelstein; Kim Sutton-Tyrrell; Rebecca C Thurston; Nanette Santoro; Barbara Sternfeld; Gail A Greendale Journal: J Clin Endocrinol Metab Date: 2012-06-21 Impact factor: 5.958
Authors: Pangaja Paramsothy; Siobán D Harlow; Michael R Elliott; Matheos Yosef; Lynda D Lisabeth; Gail A Greendale; Ellen B Gold; Sybil L Crawford; John F Randolph Journal: Menopause Date: 2015-02 Impact factor: 2.953
Authors: S K Park; S D Harlow; H Zheng; C Karvonen-Gutierrez; R C Thurston; K Ruppert; I Janssen; J F Randolph Journal: Diabet Med Date: 2017-01-04 Impact factor: 4.359
Authors: Nikki A Ford; Kaylyn L Devlin; Laura M Lashinger; Stephen D Hursting Journal: J Mammary Gland Biol Neoplasia Date: 2013-10-04 Impact factor: 2.673